Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
November 21 2017 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer
of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that Douglas M. Fambrough, Ph.D.,
president and chief executive officer, will present at the
inaugural Evercore ISI Biopharma Catalyst/Deep Dive Conference on
Thursday, November 30, 2017 at 1:35 p.m. ET. The conference will be
held at the Boston Harbor Hotel in Boston.
A live audio webcast of the presentation can be accessed on the
Investors & Media section on the Dicerna website at
www.dicerna.com. An archived replay of the webcast will be
available on the Company’s website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative,
subcutaneously delivered RNAi-based therapeutics for diseases
involving the liver, including rare diseases, chronic liver
diseases, cardiovascular diseases, and viral infectious diseases.
Dicerna is leveraging its proprietary GalXC™ RNAi technology
platform to build a broad pipeline in these core therapeutic areas,
focusing on target genes where connections between target gene and
diseases are well understood and documented. Dicerna intends to
discover, develop and commercialize novel therapeutics either on
its own or in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171121005168/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From May 2024 to Jun 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Jun 2023 to Jun 2024